Medcomtech Valuation

Is MED undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MED when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MED's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MED's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MED?

Key metric: As MED is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MED. This is calculated by dividing MED's market cap by their current revenue.
What is MED's PS Ratio?
PS Ratio	0.3x
Sales	€27.36m
Market Cap	€8.94m

MED key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1x
Enterprise Value/EBITDA	13.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MED's PS Ratio compare to its peers?

The above table shows the PS ratio for MED vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.9x
8372 Grand Brilliance Group Holdings	0.9x	n/a	HK$71.2m
TM Techno Medical	0.5x	n/a	฿357.3m
IBLHL IBL HealthCare	0.9x	n/a	PK₨3.3b
RAWILL R.A. Williams Distributors	1.1x	n/a	JA$1.7b
MED Medcomtech	0.3x	n/a	€8.9m

Price-To-Sales vs Peers: MED is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.5x).

Price to Sales Ratio vs Industry

How does MED's PS Ratio compare vs other companies in the European Healthcare Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: MED is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Healthcare industry average (0.7x).

Price to Sales Ratio vs Fair Ratio

What is MED's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MED PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MED's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.